Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney - Takeaways - MDSpire

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney

  • By

  • Zhigang Yao

  • Chenghao Zhanghuang

  • Nian Zhou

  • Jinrong Li

  • Zipeng Hao

  • Bing Yan

  • Hui Zhao

  • June 10, 2026

  • 0 min

Share

  • 1

    Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive pediatric cancer with poor survival rates despite multimodal treatment.

  • 2

    Intensified treatment strategies have improved outcomes for localized MRTK but have not significantly benefited advanced-stage or metastatic cases.

  • 3

    The loss of SMARCB1 is a key molecular feature of MRTK, guiding diagnosis and potential targeted therapies.

  • 4

    Current treatment relies on surgery, chemotherapy, and radiotherapy, but their effectiveness is limited by the tumor's biological aggressiveness.

  • 5

    Future advancements in MRTK treatment will depend on molecular profiling and collaborative trials to develop precision therapies.

Original Source(s)

Current treatment landscape and translational priorities in malignant rhabdoid tumor of the kidney

  • by Zhigang Yao, Chenghao Zhanghuang, Nian Zhou, Jinrong Li, Zipeng Hao, Bing Yan, Hui Zhao

  • June 10, 2026

Related Content

Editorial: New Insights on Sialic Acid and Sialylated Glycans in the Tumorigenic Process

Long-term results after surgical resection of intrahepatic cholangiocarcinoma before and since the BILCAP era

Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes